Palbociclib Submitted to FDA for Breast Cancer Approval

Share this content:

the Cancer Therapy Advisor take:

Pfizer has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for palbociclib for the treatment of estrogen receptor-positive and human epidermal growth factor 2-negative advanced breast cancer in post-menopausal women.


Palbociclib is an orally administered cyclin-dependent kinases 4 and 6 (CDK4/CDK6) selective inhibitor to be used in conjunction with letrozole, an aromatase inhibitor.


Approval of the new drug application would be based on the phase 2 PALOMA-1 study, a randomized trial that compared palbociclib plus letrozole with letrozole alone. The study found that progression-free survival was 20.2 months in the palbociclib plus letrozole group and 10.2 months in the letrozole alone group, meaning palbociclib reduces the risk of disease progression by 51%. Overall survival was not significantly extended in the palbociclib group. Common adverse effects were bone marrow suppression and fatigue.


Palbociclib is currently being tested in two phase 3 studies. In the PALOMA-2 study, palbociclib is being studied in combination with letrozole for the treatment of advanced metastatic breast cancer. The drug is also being studied with fulvestrant in the PALOMA-3 study for the treatment of metastatic breast cancer.

Erlotinib and Gastric Acid Suppression
Pfizer is seeking approval for palbociclib to treat post-menopausal women with breast cancer.

US-based pharmaceutical company Pfizer has submitted a new drug application (NDA) for palbociclib to the US Food and Drug Administration (FDA).

The company is seeking approval for palbociclib, in combination with letrozole, to treat post-menopausal women with estrogen receptor positive (ER+) and human epidermal growth factor receptor two negative (HER2-) advanced breast cancer.

Pfizer Oncology president Garry Nicholson said: "Today's submission marks an important milestone for Pfizer and palbociclib, and a potential advance for women with advanced breast cancer."

READ FULL ARTICLE From Pharmaceutical Technology

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs